Cartesian Therapeutics, Inc. Revenue, Remaining Performance Obligation, Percentage
Cartesian Therapeutics, Inc. (RNAC) had Revenue, Remaining Performance Obligation, Percentage of 8.80% as of 2019-09-30, per its 10-Q filed 2019-11-08.
Discontinued › Notes
us-gaap:RevenueRemainingPerformanceObligationPercentage · last filed 2019-11-08
- 2019-09-30: Revenue, Remaining Performance Obligation, Percentage 8.80%.
- 2019-06-30: Revenue, Remaining Performance Obligation, Percentage 8.80%.
- 2019-03-31: Revenue, Remaining Performance Obligation, Percentage 8.90%.
- 2018-12-31: Revenue, Remaining Performance Obligation, Percentage 8.90%.
| Period end | Revenue, Remaining Performance Obligation, Percentage |
|---|---|
| 2019-09-30 | 8.80% 10-Q · filed 2019-11-08 |
| 2019-06-30 | 8.80% 10-Q · filed 2019-08-08 |
| 2019-03-31 | 8.90% 10-Q · filed 2019-05-09 |
| 2018-12-31 | 8.90% 10-K · filed 2019-03-15 |
| 2018-09-30 | 8.90% 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |